New observational study launched to assess PML survivors

Written by Alice Weatherston

Inhibikase Therapeutics Inc. have today announced the launch of an observational clinical study in patients with progressive multifocal leukoencephalopathy (PML), which is a possible side effect of a variety of drugs used in treatment for diseases such as multiple sclerosis, Crohn’s disease, ulcerative colitis and hematologic cancers as well as HIV/AIDS patients. JC Virus (JCV) is the primary cause of PML and its transport from the kidney into the brain can be induced by a range of medications. Once in the brain JCV is capable of causing severe and irreversible damage which can lead to death. “The company has a...

To view this content, please register now for access

It's completely free